Ipafricept - Bayer HealthCare Pharmaceuticals/OncoMed Pharmaceuticals

Drug Profile

Ipafricept - Bayer HealthCare Pharmaceuticals/OncoMed Pharmaceuticals

Alternative Names: Fzd8-Fc; Ipafricept; OMP 54F28

Latest Information Update: 07 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bayer HealthCare Pharmaceuticals; OncoMed Pharmaceuticals
  • Class Antineoplastics; Disulfides; Immunoglobulin Fc fragments; Immunoglobulin fusion proteins; Proteins; Recombinant fusion proteins
  • Mechanism of Action Frizzled 8 receptor modulators; Wnt protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Hepatocellular carcinoma; Ovarian cancer; Pancreatic cancer; Solid tumours

Highest Development Phases

  • Suspended Hepatocellular carcinoma; Ovarian cancer; Pancreatic cancer; Solid tumours

Most Recent Events

  • 01 Jul 2017 OncoMed Pharmaceuticals completes a phase I trial for Hepatocellular carcinoma (Combination therapy, First-line therapy, Late-stage disease, Metastatic disease) in USA (IV) (NCT02069145)
  • 08 May 2017 OncoMed Pharmaceuticals suspends patient enrolment in a phase I trial for Hepatocellular carcinoma (Combination therapy, First-line therapy, Late-stage disease, Metastatic disease) in USA following a recent bone adverse event that occurred in a patient receiving vantictumab plus paclitaxel in the phase Ib HER2-negative breast cancer trial (IV)
  • 08 May 2017 OncoMed Pharmaceuticals suspends patient enrolment in a phase I trial in Pancreatic cancer (First-line therapy, Combination therapy, Late-stage disease, Metastatic disease) in USA following a recent bone adverse event that occurred in a patient receiving vantictumab plus paclitaxel in a phase Ib HER2-negative breast cancer trial (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top